IP Library Granted Patent US 12,472,197
Granted Patent B2
US 12,472,197 · App. 17/995,793 · Granted Nov 18, 2025

Methods, compositions, and dosing regimens for treatment of SARS-CoV-2 infections

Inventors: Yarlagadda S. Babu (Birmingham, AL); Amanda Mathis (Raleigh, NC); William P. Sheridan (Durham, NC)
Assignee: Island Pharmaceuticals, Ltd.
A61K31/7064A61P31/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,472,197
App. No.
17/995,793
Granted
Nov 18, 2025
Kind
B2
Abstract

Provided are compounds of the formula I and pharmaceutically acceptable salts, solvates, and hydrates thereof, for use in treating or suppressing a SARS-CoV-2 infection in a subject. A novel dosing regimen for administration of the disclosed compounds is also provided comprising administering at least one loading dose and at least one maintenance dose of the disclosed compound. The compounds of the disclosure are characterized, in part, by favorable pharmacokinetics for the active pharmaceutical ingredient, particularly in conjunction with the dosing regimen described.

Claims (42)

1 . A method of treating a subject suffering from a SARS-COV-2 infection, the method comprising administering to the subject an effective amount of a compound of formula I,

or a pharmaceutically acceptable salt, solvate, or hydrate thereof,

wherein:

A is OH or NH 2 ; and

B is H or NH 2 ;

and wherein the administering step comprises administering at least one loading dose and a plurality of maintenance doses according to a course of treatment.

2 . The method of claim 1 , wherein A is NH 2 and B is H.

3 . The method of claim 2 , wherein the effective amount is from 10 mg/kg/day to 14 mg/kg/day on day 1 of the course of treatment and from 2 mg/kg/day to 6 mg/kg/day on every other day of the course of treatment and the effective amount is administered as a single loading dose and the plurality of maintenance doses.

4 . The method of claim 3 , wherein the effective amount is administered as two doses each day.

5 . The method of claim 4 , wherein the effective amount is administered as the single loading dose of 8 mg/kg to 12 mg/kg as a first dose of the course of treatment, a maintenance dose of 1 mg/kg to 3 mg/kg as a second dose of the course of treatment, and as the plurality of maintenance doses of 1 mg/kg to 3 mg/kg for the remainder of the course of treatment.

6 . The method of claim 4 , wherein the effective amount is 12 mg/kg/day on day 1 of the course of treatment, wherein the effective amount on day 1 is administered as the single loading dose of 10 mg/kg and as the maintenance dose of 2 mg/kg, and the effective amount on every other day of the course of treatment is 4 mg/kg/day, wherein the effective amount on every other day of the course of treatment is administered as the plurality of maintenance dose of 2 mg/kg two times per day.

7 . The method of claim 2 , wherein the effective amount is from 13 mg/kg/day to 17 mg/kg/day on day 1 of the course of treatment and from 8 mg/kg/day to 12 mg/kg/day on every other day of the course of treatment and the effective amount is administered as a single loading dose and the plurality of maintenance doses.

8 . The method of claim 7 , wherein the effective amount is administered as two doses each day.

9 . The method of claim 8 , wherein the effective amount is administered as the single loading dose of 8 mg/kg to 12 mg/kg as a first dose of the course of treatment, a maintenance dose of 3 mg/kg to 7 mg/kg as a second dose of the course of treatment, and as the plurality of maintenance doses of 3 mg/kg to 7 mg/kg for the remainder of the course of treatment.

10 . The method of claim 8 , wherein the effective amount is 15 mg/kg/day on day 1 of the course of treatment, wherein the effective amount on day 1 is administered as the single loading dose of 10 mg/kg and as the maintenance dose of 5 mg/kg, and the effective amount on every other day of the course of treatment is 10 mg/kg/day, wherein the effective amount on every other day of the course of treatment is administered as the plurality of maintenance dose of 5 mg/kg.

11 . The method of claim 2 , wherein the effective amount is from 23 mg/kg/day to 27 mg/kg/day on day 1 of the course of treatment and from 8 mg/kg/day to 12 mg/kg/day on every other day of the course of treatment and the effective amount is administered as a single loading dose and the plurality of maintenance doses.

12 . The method of claim 11 , wherein the effective amount is administered as two doses each day.

13 . The method of claim 12 , wherein the effective amount is administered as the single loading dose of 18 mg/kg to 22 mg/kg as a first dose of the course of treatment, a maintenance dose of 3 mg/kg to 7 mg/kg as a second dose of the course of treatment, and as the plurality of maintenance doses of 3 mg/kg to 7 mg/kg for the remainder of the course of treatment.

14 . The method of claim 12 , wherein the effective amount is 25 mg/kg/day on day 1 of the course of treatment, wherein the effective amount on day 1 is administered as the single loading dose of 20 mg/kg and as a maintenance dose of 5 mg/kg, and the effective amount on every other day of the course of treatment is 10 mg/kg/day, wherein the effective amount on every other day of the course of treatment is administered as the plurality of maintenance dose of 5 mg/kg.

15 . The method of claim 1 , wherein the course of treatment is initiated after the subject has been infected with the SARS-COV-2 infection.

16 . A method for reducing a viral titer of SARS-COV-2 in a bodily fluid, tissue or cell of a subject suffering from a SARS-COV-2 infection, the method comprising administering to the subject an effective amount of a compound of formula I,

or a pharmaceutically acceptable salt, solvate, or hydrate thereof,

wherein:

A is OH or NH 2 ; and

B is H or NH 2 ;

and wherein the administering step comprises administering at least one loading dose and a plurality of maintenance doses according to a course of treatment.

17 . The method of claim 16 , wherein A is NH 2 and B is H.

18 . The method of claim 17 , wherein the effective amount is from 10 mg/kg/day to 14 mg/kg/day on day 1 of the course of treatment and from 2 mg/kg/day to 6 mg/kg/day on every other day of the course of treatment and the effective amount is administered as a single loading dose and the plurality of maintenance doses.

19 . The method of claim 18 , wherein the effective amount is administered as two doses each day.

20 . The method of claim 19 , wherein the effective amount is administered as the single loading dose of 8 mg/kg to 12 mg/kg as a first dose of the course of treatment, a maintenance dose of 1 mg/kg to 3 mg/kg as a second dose of the course of treatment, and as the plurality of maintenance doses of 1 mg/kg to 3 mg/kg for the remainder of the course of treatment.

21 . The method of claim 19 , wherein the effective amount is 12 mg/kg/day on day 1 of the course of treatment, wherein the effective amount on day 1 is administered as the single loading dose of 10 mg/kg and as the maintenance dose of 2 mg/kg, and the effective amount on every other day of the course of treatment is 4 mg/kg/day, wherein the effective amount on every other day of the course of treatment is administered as the plurality of maintenance dose of 2 mg/kg two times per day.

22 . The method of claim 17 , wherein the effective amount is from 13 mg/kg/day to 17 mg/kg/day on day 1 of the course of treatment and from 8 mg/kg/day to 12 mg/kg/day on every other day of the course of treatment and the effective amount is administered as a single loading dose and the plurality of maintenance doses.

23 . The method of claim 22 , wherein the effective amount is administered as two doses each day.

24 . The method of claim 23 , wherein the effective amount is administered as the single loading dose of 8 mg/kg to 12 mg/kg as a first dose of the course of treatment, a maintenance dose of 3 mg/kg to 7 mg/kg as a second dose of the course of treatment, and as the plurality of maintenance doses of 3 mg/kg to 7 mg/kg for the remainder of the course of treatment.

25 . The method of claim 23 , wherein the effective amount is 15 mg/kg/day on day 1 of the course of treatment, wherein the effective amount on day 1 is administered as the single loading dose of 10 mg/kg and as the maintenance dose of 5 mg/kg, and the effective amount on every other day of the course of treatment is 10 mg/kg/day, wherein the effective amount on every other day of the course of treatment is administered as the plurality of maintenance dose of 5 mg/kg.

26 . The method of claim 17 , wherein the effective amount is from 23 mg/kg/day to 27 mg/kg/day on day 1 of the course of treatment and from 8 mg/kg/day to 12 mg/kg/day on every other day of the course of treatment and the effective amount is administered as a single loading dose and the plurality of maintenance doses.

27 . The method of claim 26 , wherein the effective amount is administered as two doses each day.

28 . The method of claim 27 , wherein the effective amount is administered as the single loading dose of 18 mg/kg to 22 mg/kg as a first dose of the course of treatment, a maintenance dose of 3 mg/kg to 7 mg/kg as a second dose of the course of treatment, and as the plurality of maintenance doses of 3 mg/kg to 7 mg/kg for the remainder of the course of treatment.

29 . The method of claim 27 , wherein the effective amount is 25 mg/kg/day on day 1 of the course of treatment, wherein the effective amount on day 1 is administered as the single loading dose of 20 mg/kg and as a maintenance dose of 5 mg/kg, and the effective amount on every other day of the course of treatment is 10 mg/kg/day, wherein the effective amount on every other day of the course of treatment is administered as the plurality of maintenance dose of 5 mg/kg.

30 . The method of claim 16 , wherein the course of treatment is initiated after the subject has been infected with the SARS-COV-2 infection.

31 . The method of claim 16 , wherein the administering step is intravenous administration.

32 . The method of claim 1 , wherein the administering step is intravenous administration.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 14, 2025
From: BIOCRYST, INC.
To: ISLAND PHARMACEUTICALS, LTD
Reel/Frame 072560/0239 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 16, 2023
From: BABU, YARLAGADDA S.; MATHIS, AMANDA; SHERIDAN, WILLIAM P.
To: BIOCRYST PHARMACEUTICALS, INC.
Reel/Frame 064607/0359 →
Continuity (2)
Provisional Application 63006186 · Apr 7, 2020
Related Publication 20230158054A1 · May 25, 2023
References Cited (5)
US 9492452B2 · Bantia et al. · 2016 [cited by applicant]
WO 2013158746A1 · 2013 [cited by applicant]
WO 2016069826A1 · 2016 [cited by applicant]
Ko WC, Rolain JM, Lee NY, Chen PL, Huang CT, Lee PI, Hsueh PR. Arguments in favour of remdesivir for treating SARS-CoV-2 infections. International journal of antimicrobial agents. Apr. 1, 2020;55(4):105933. [cited by examiner]
Yao, et al., “In Vitro Antiviral Activity and Projections of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Repiratory Syndrome Coronavirus 2 (SARS-CoV-2),” Clinical Infectious Disease, … [cited by applicant]